卒中患者使用选择性5-羟色胺再摄取抑制剂与骨折风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入4项为期6个月的随机对照试验(共6549例卒中幸存者),评估SSRI与骨折风险的关系。结果显示,与安慰剂相比,使用SSRI 6个月使骨折风险增加,风险比为2.36(95%CI 1.64–3.39);跌倒、癫痫发作和卒中复发的风险无统计学显著增加。
要点
- 跌倒、癫痫发作和卒中复发风险未见统计学显著升高。
- 证据仅来自氟西汀和西酞普兰的RCT,推广至其他SSRI需谨慎。
核心结论
- 基于氟西汀和西酞普兰的随机对照试验,卒中幸存者使用SSRI 6个月使骨折风险加倍。
研究设计与样本
- 系统综述与荟萃分析,纳入4项为期6个月的随机对照试验,共6549例成人出血性或缺血性卒中幸存者。
主要发现
- 与安慰剂相比,SSRI治疗6个月增加骨折风险,风险比为2.36(95%CI 1.64–3.39)。
- 跌倒、癫痫发作和卒中复发的风险无统计学显著增加。
关键数值与推荐
- SSRI治疗6个月骨折风险比:2.36(95%CI 1.64–3.39)。
临床怎么用
- 卒中幸存者使用SSRI(尤其氟西汀或西酞普兰)时应评估骨折风险并采取预防措施。
局限性
- 仅纳入氟西汀和西酞普兰的研究,结果推广至其他SSRI不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Stroke survivors have an increased risk of depression and bone fractures. Selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased risk of fractures in observational studies. Several randomized controlled trials (RCTs) reporting the effect of SSRIs on the risk of fractures in stroke survivors have been published recently but have not been subject to a meta-analysis. We aimed to determine the risk of fractures associated with the use of SSRIs, and the risk of falls, seizures, and recurrent strokes as possible mediators of fractures, in stroke survivors. METHODS: We conducted a systematic review and meta-analysis of RCTs of SSRIs in stroke survivors according to a protocol registered in PROSPERO (CRD42020192632). Web of Science, EMBASE, PsycINFO, and Ovid Medline/PubMed bibliographic databases, clinical trial registers, and grey literature sources were searched. RCTs of SSRIs versus placebo or no intervention that report the risk of fractures in adult survivors of hemorrhagic or ischemic stroke were included. Two reviewers independently screened search results and extracted data. Meta-analyses were conducted for each outcome using the Mantel-Haenszel random-effects models. RESULTS: The searches yielded 683 records, of which 4 RCTs of 6 months duration with a total of 6549 participants were included in the meta-analysis: 3 studies of fluoxetine and 1 study of citalopram. Treatment with an SSRI for 6 months increased the risk of fractures with a risk ratio of 2.36 (95% CI, 1.64–3.39) compared with placebo. The risk of falls, seizures, and recurrent stroke was not statistically significantly increased. Only studies of fluoxetine and citalopram were available for inclusion in the review, and hence the generalizability of the findings to other SSRIs is uncertain. CONCLUSIONS: Based on available RCTs of fluoxetine and citalopram, SSRIs used for 6 months doubled the risk of fractures in stroke survivors. REGISTRATION: https://www.crd.york.ac.uk/prospero/; Unique identifier: CRD42020192632.
引用
- Jones JS, Kimata R, Almeida OP, et al. Risk of Fractures in Stroke Patients Treated With a Selective Serotonin Reuptake Inhibitor: A Systematic Review and Meta-Analysis. Stroke. 2021. PMID: 34167325. doi:10.1161/STROKEAHA.120.032973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。